EcoDrugPlus

Trace Amine-Associated Receptor 1-Like

Ensembl ID : ENSMAMG00000026440
Gene Symbol: LOC113137539
2 Cross references
389 Possible Orthologues:

Trace Amine-Associated Receptor 1-Like

Ensembl ID : ENSMAMG00000005940
Gene Symbol: LOC113137546
2 Cross references
348 Possible Orthologues:

Trace Amine-Associated Receptor 1-Like

Ensembl ID : ENSMAMG00000024652
Gene Symbol: LOC113137542
2 Cross references
389 Possible Orthologues:

Trace Amine-Associated Receptor 1-Like

Ensembl ID : ENSMAMG00000005966
Gene Symbol: LOC113137369
2 Cross references
374 Possible Orthologues:

Trace Amine-Associated Receptor 1-Like

Ensembl ID : ENSMAMG00000028186
Gene Symbol: LOC113137373
2 Cross references
428 Possible Orthologues:

Trace Amine-Associated Receptor 1-Like

Ensembl ID : ENSMAMG00000027122
Gene Symbol: LOC113137374
2 Cross references
428 Possible Orthologues:

Trace Amine-Associated Receptor 1-Like

Ensembl ID : ENSMAMG00000005874
Gene Symbol: LOC113137534
2 Cross references
356 Possible Orthologues:

Trace Amine-Associated Receptor 1-Like

Ensembl ID : ENSMAMG00000006017
Gene Symbol: LOC113137543
2 Cross references
389 Possible Orthologues:

Transforming Growth Factor, Beta Receptor 1 B

Ensembl ID : ENSMAMG00000021763
Gene Symbol: TGFBR1B
3 Cross references
204 Possible Orthologues:

Transient Receptor Potential Cation Channel, Subfamily A, Member 1b

Ensembl ID : ENSMAMG00000023050
Gene Symbol: TRPA1B
3 Cross references
200 Possible Orthologues:

Transmembrane O-Methyltransferase Homolog

Ensembl ID : ENSMAMG00000015711
Gene Symbol: LOC113144720
2 Cross references
177 Possible Orthologues:

Transmembrane P24 Trafficking Protein 3

Ensembl ID : ENSMAMG00000001167
Gene Symbol: LOC113122229
2 Cross references
186 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).